Van Poznak CH - Search Results

1

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.

Eisen A, Somerfield MR, Accordino MK, Blanchette PS, Clemons MJ, Dhesy-Thind S, Dillmon MS, D'Oronzo S, Fletcher GG, Frank ES, Hallmeyer S, Makhoul I, Moy B, Thawer A, Wu JY, Van Poznak CH. Eisen A, et al. Among authors: van poznak ch. J Clin Oncol. 2022 Mar 1;40(7):787-800. doi: 10.1200/JCO.21.02647. Epub 2022 Jan 18. J Clin Oncol. 2022. PMID: 35041467

2

How are bisphosphonates used today in breast cancer clinical practice?

Van Poznak C. Van Poznak C. Semin Oncol. 2001 Aug;28(4 Suppl 11):69-74. doi: 10.1053/sonc.2001.25445. Semin Oncol. 2001. PMID: 11544580 Review.

3

Bone integrity and bone metastases in breast cancer.

Van Poznak C, Nadal C. Van Poznak C, et al. Curr Oncol Rep. 2006 Jan;8(1):22-8. doi: 10.1007/s11912-006-0005-9. Curr Oncol Rep. 2006. PMID: 16464399

4

Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.

Van Poznak C, Estilo C. Van Poznak C, et al. Oncology (Williston Park). 2006 Aug;20(9):1053-62; discussion 1065-6. Oncology (Williston Park). 2006. PMID: 16986349 Free article. Review.

5

Bisphosphonates for breast cancer: questions answered, questions remaining.

Layman R, Olson K, Van Poznak C. Layman R, et al. Hematol Oncol Clin North Am. 2007 Apr;21(2):341-67. doi: 10.1016/j.hoc.2007.03.004. Hematol Oncol Clin North Am. 2007. PMID: 17512453 Review.

6

Significance and impact of bisphosphonate-induced acute phase responses.

Olson K, Van Poznak C. Olson K, et al. J Oncol Pharm Pract. 2007 Dec;13(4):223-9. doi: 10.1177/1078155207080806. J Oncol Pharm Pract. 2007. PMID: 18045781 Review.

7

Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.

Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R. Van Poznak C, et al. J Clin Oncol. 2010 Feb 20;28(6):967-75. doi: 10.1200/JCO.2009.24.5902. Epub 2010 Jan 11. J Clin Oncol. 2010. PMID: 20065185 Clinical Trial.

8

Bisphosphonates: do we know their role in adjuvant breast cancer treatment?

Barginear MF, Van Poznak C. Barginear MF, et al. Oncology (Williston Park). 2010 May;24(6):475, 478, 480. Oncology (Williston Park). 2010. PMID: 20568588 Free PMC article. No abstract available.

9

American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, Zuckerman DS, Von Roenn JH; American Society of Clinical Oncology. Van Poznak CH, et al. J Clin Oncol. 2011 Mar 20;29(9):1221-7. doi: 10.1200/JCO.2010.32.5209. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343561

10

American society of clinical oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer.

Van Poznak CH, Von Roenn JH, Temin S. Van Poznak CH, et al. J Oncol Pract. 2011 Mar;7(2):117-21. doi: 10.1200/JOP.2011.000212. J Oncol Pract. 2011. PMID: 21731520 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

137 results

Search Page